Logo image of SEEL

SEELOS THERAPEUTICS INC (SEEL) Stock Fundamental Analysis

NASDAQ:SEEL - Nasdaq - US81577F3073 - Common Stock - Currency: USD

1.28  -1.17 (-47.76%)

After market: 1.45 +0.17 (+13.28%)

Fundamental Rating

2

SEEL gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 194 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of SEEL have multiple concerns. SEEL is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

SEEL had negative earnings in the past year.
SEEL had a negative operating cash flow in the past year.
In the past 5 years SEEL always reported negative net income.
SEEL had a negative operating cash flow in each of the past 5 years.
SEEL Yearly Net Income VS EBIT VS OCF VS FCFSEEL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -20M -40M -60M

1.2 Ratios

Looking at the Return On Assets, with a value of 171.82%, SEEL belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
Industry RankSector Rank
ROA 171.82%
ROE N/A
ROIC N/A
ROA(3y)-367.19%
ROA(5y)-334.54%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SEEL Yearly ROA, ROE, ROICSEEL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200K 400K 600K

1.3 Margins

SEEL has a Profit Margin of 203.13%. This is amongst the best in the industry. SEEL outperforms 99.48% of its industry peers.
SEEL does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) 203.13%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SEEL Yearly Profit, Operating, Gross MarginsSEEL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -2K -4K -6K -8K -10K

More info and screens

0

2. Health

2.1 Basic Checks

The number of shares outstanding for SEEL has been increased compared to 1 year ago.
SEEL has more shares outstanding than it did 5 years ago.
The debt/assets ratio for SEEL is higher compared to a year ago.
SEEL Yearly Shares OutstandingSEEL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 200K 400K 600K 800K 1M
SEEL Yearly Total Debt VS Total AssetsSEEL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

2.2 Solvency

Based on the Altman-Z score of -203.76, we must say that SEEL is in the distress zone and has some risk of bankruptcy.
SEEL's Altman-Z score of -203.76 is on the low side compared to the rest of the industry. SEEL is outperformed by 97.94% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -203.76
ROIC/WACCN/A
WACCN/A
SEEL Yearly LT Debt VS Equity VS FCFSEEL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M -40M -60M

2.3 Liquidity

A Current Ratio of 0.08 indicates that SEEL may have some problems paying its short term obligations.
The Current ratio of SEEL (0.08) is worse than 99.48% of its industry peers.
A Quick Ratio of 0.08 indicates that SEEL may have some problems paying its short term obligations.
SEEL has a Quick ratio of 0.08. This is amonst the worse of the industry: SEEL underperforms 98.97% of its industry peers.
Industry RankSector Rank
Current Ratio 0.08
Quick Ratio 0.08
SEEL Yearly Current Assets VS Current LiabilitesSEEL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for SEEL have decreased strongly by -318.47% in the last year.
SEEL shows a strong growth in Revenue. In the last year, the Revenue has grown by 76.05%.
EPS 1Y (TTM)-318.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%101.27%
Revenue 1Y (TTM)76.05%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%11.9%

3.2 Future

SEEL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 41.17% yearly.
SEEL is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 195.91% yearly.
EPS Next Y97.05%
EPS Next 2Y41.17%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-81.25%
Revenue Next 2Y321.31%
Revenue Next 3Y402.41%
Revenue Next 5Y195.91%

3.3 Evolution

SEEL Yearly Revenue VS EstimatesSEEL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M 500M
SEEL Yearly EPS VS EstimatesSEEL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -50 -100 -150

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for SEEL. In the last year negative earnings were reported.
Also next year SEEL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SEEL Price Earnings VS Forward Price EarningsSEEL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SEEL Per share dataSEEL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60

4.3 Compensation for Growth

A more expensive valuation may be justified as SEEL's earnings are expected to grow with 41.17% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.17%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SEEL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SEELOS THERAPEUTICS INC

NASDAQ:SEEL (10/15/2024, 8:00:02 PM)

After market: 1.45 +0.17 (+13.28%)

1.28

-1.17 (-47.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-02 2024-08-02/bmo
Earnings (Next)11-12 2024-11-12/bmo
Inst Owners21.58%
Inst Owner Change-19.13%
Ins Owners73.41%
Ins Owner Change0%
Market Cap563.20K
Analysts85.71
Price Target122.4 (9462.5%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)56.05%
Min Revenue beat(2)22.88%
Max Revenue beat(2)89.22%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.28
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-45.32
EYN/A
EPS(NY)-0.33
Fwd EYN/A
FCF(TTM)-30.17
FCFYN/A
OCF(TTM)-30.17
OCFYN/A
SpS4.58
BVpS-63.94
TBVpS-63.94
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 171.82%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 203.13%
GM N/A
FCFM N/A
ROA(3y)-367.19%
ROA(5y)-334.54%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.85
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.08
Quick Ratio 0.08
Altman-Z -203.76
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-318.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%101.27%
EPS Next Y97.05%
EPS Next 2Y41.17%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)76.05%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%11.9%
Revenue Next Year-81.25%
Revenue Next 2Y321.31%
Revenue Next 3Y402.41%
Revenue Next 5Y195.91%
EBIT growth 1Y46.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y79.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y79.98%
OCF growth 3YN/A
OCF growth 5YN/A